Praxis Precision Medicines Inc (PRAX) - News Archive

In recent developments within the biopharmaceutical sector, Pomerantz LLP has initiated an investigation aimed at safeguarding the interests of investors in Praxis Precision Medicines, Inc. (NASDAQ: PRAX). This article...

Praxis Precision Medicines: Strategic Stock Award to Enhance Team Capabilities Amid Promising Epilepsy BreakthroughsIn a recent development poised to influence both its human resources and financial narratives, Praxis P...

In a significant stride towards innovative epilepsy management, Praxis Precision Medicines has unveiled promising topline results from its EMBOLD study, showcasing the disease-modifying potential of relutrigine for pati...

Praxis Precision Medicines Grants Stock Options and Restricted Stock Units to New EmployeeBOSTON, June 4, 2024 - Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a pioneering clinical-stage biopharmaceutical company foc...

Praxis Precision Medicines, a clinical-stage biopharmaceutical company specializing in the development of therapies for central nervous system disorders, has made significant announcements regarding inducement grants an...

Praxis Precision Medicines to Participate in Upcoming April ConferencesBOSTON, April 05, 2024 - Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company specializing in the translation...

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company specializing in therapies for central nervous system disorders, has announced the pricing of its underwritten public offering. The company pla...

Boston-based biopharmaceutical company, Praxis Precision Medicines, Inc. (NASDAQ: PRAX), has unveiled plans for a public offering of its common stock, alongside prefunded warrants for certain investors. The offering is...

Praxis Precision Medicines, Inc. made an exciting announcement regarding inducement grants under Nasdaq Listing Rule 5635(c)(4). This move comes at a time when the company s share price is soaring, indicating its positi...

Leading biopharmaceutical company, Praxis Precision Medicines, Inc. (NASDAQ: PRAX), has recently made a significant breakthrough by successfully pricing its underwritten public offering at $150.0 million. The offering,...

BOSTON, Jan. 10, 2024 - Praxis Precision Medicines, a leading clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, has recently announced its plans for a p...

Praxis Precision Medicines, a leading biopharmaceutical company focused on developing precision therapies for central nervous system disorders, recently released an update on the progress of its clinical stage portfolio...

Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China: Collaboration leverages Tenacia s expertise in central nervous system drug devel...